FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1885-1890 October 28, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

When a great profession and the forces of capitalism interact, drama is likely to result. This has certainly been the case where the profession of medicine and the pharmaceutical industry are concerned. On display in the relationship between doctors and drug companies are the grandeur and weaknesses of the medical profession — its noble aspirations and its continuing inability to fulfill them. Also on display are the power, social contributions, and occasional venality of a very profitable industry whose products contribute in important ways to the health and longevity of the American people but that at times employs methods that . . . [Full Text of this Article]

The Nature and Extent of the Relationships

Consequences of the Relationships

Efforts to Manage Relationships

Future Developments

Source Information

From the Institute for Health Policy, Massachusetts General Hospital, Partners Health Care System, Boston.

Related Letters:

Doctors and Drug Companies
Lambert L. A., Jenny-Avital E. R., Blumenthal D.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:733-734, Feb 17, 2005. Correspondence

This article has been cited by other articles:

• Sondergaard, J., Vach, K., Kragstrup, J., Andersen, M. (2009). Impact of pharmaceutical representative visits on GPs' drug preferences. Fam Pract 26: 204-209 [Abstract] [Full Text]  
• Greenland, P. (2009). Time for the Medical Profession to Act: New Policies Needed Now on Interactions Between Pharmaceutical Companies and Physicians. Arch Intern Med 169: 829-831 [Full Text]  
• Rothman, D. J., McDonald, W. J., Berkowitz, C. D., Chimonas, S. C., DeAngelis, C. D., Hale, R. W., Nissen, S. E., Osborn, J. E., Scully, J. H. Jr, Thomson, G. E., Wofsy, D. (2009). Professional Medical Associations and Their Relationships With Industry: A Proposal for Controlling Conflict of Interest. JAMA 301: 1367-1372 [Abstract] [Full Text]  
• Elkind, M. S.V. (2009). Teaching the next generation of neurologists. Neurology 72: 657-663 [Abstract] [Full Text]  
• Rothman, D. J., Chimonas, S. (2008). New Developments in Managing Physician-Industry Relationships. JAMA 300: 1067-1069 [Full Text]  
• Smith, M. J. (2008). 'Public psychiatry': a neglected professional role?. Adv. Psychiatr. Treat. 14: 339-346 [Abstract] [Full Text]  
• Carroll, A. E., Vreeman, R. C., Buddenbaum, J., Inui, T. S. (2007). To What Extent Do Educational Interventions Impact Medical Trainees' Attitudes and Behaviors Regarding Industry-Trainee and Industry-Physician Relationships?. Pediatrics 120: e1528-e1535 [Abstract] [Full Text]  
• Campbell, E. G., Weissman, J. S., Ehringhaus, S., Rao, S. R., Moy, B., Feibelmann, S., Goold, S. D. (2007). Institutional Academic Industry Relationships. JAMA 298: 1779-1786 [Abstract] [Full Text]  
• Tonelli, M. R. (2007). Conflict of Interest in Clinical Practice. Chest 132: 664-670 [Abstract] [Full Text]  
• Pinto, S. L, Lipowski, E., Segal, R., Kimberlin, C., Algina, J. (2007). Physicians' intent to comply with the American Medical Association's guidelines on gifts from the pharmaceutical industry. J. Med. Ethics 33: 313-319 [Abstract] [Full Text]  
• Ingelfinger, J. R. (2007). Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions. CJASN 2: 415-417 [Full Text]  
• Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., Blumenthal, D. (2007). A National Survey of Physician-Industry Relationships. NEJM 356: 1742-1750 [Abstract] [Full Text]  
• Jagsi, R. (2007). Conflicts of Interest and the Physician-Patient Relationship in the Era of Direct-to-Patient Advertising. JCO 25: 902-905 [Full Text]  
• Florentinus, S. R, van Hulten, R., Kloth, M. E., Heerdink, E. R, Griens, A. F., Leufkens, H. G., Groenewegen, P. P, for the Netherlands Institute for Health Services, (2007). The Effect of Pharmacotherapy Audit Meetings on Early New Drug Prescribing by General Practitioners. The Annals of Pharmacotherapy 41: 319-324 [Abstract] [Full Text]  
• Jibson, M. D. (2007). Interactions Between Physicians and Industry: A Guide for Clinicians. Focus 5: 398-406 [Abstract] [Full Text]  
• Coyne, D. W. (2007). Influence of Industry on Renal Guideline Development. CJASN 2: 3-7 [Full Text]  
• Psaty, B. M., Rennie, D. (2006). Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry. JAMA 295: 2787-2790 [Full Text]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Yawn, B. P. (2006). Publication of Market-Driven Research in Medical Journals-Reply-I. Mayo Clin Proc. 81: 850-851 [Full Text]  
• Johnson, D. H. (2006). ASCO in the 21st Century: Challenges and Opportunities--ASCO Presidential Address 2005. JCO 24: 1967-1971 [Full Text]  
• Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., Goldman, J., Kassirer, J. P., Kimball, H., Naughton, J., Smelser, N. (2006). Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA 295: 429-433 [Abstract] [Full Text]  
• McKoy, J. M., Lyons, E. A., Obadina, E., Carson, K., Pickard, A. S., Schellhammer, P., McLeod, D., Boyd, C. E., McWilliams, N., Sartor, O., Schumock, G. T., McCaffery, K., Bennett, C. L. (2005). Caveat Medicus: Consequences of Federal Investigations of Marketing Activities of Pharmaceutical Suppliers of Prostate Cancer Drugs. JCO 23: 8894-8905 [Abstract] [Full Text]  
• Camilleri, M., Gamble, G. L., Kopecky, S. L., Wood, M. B., Hockema, M. L. (2005). Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy. Mayo Clin Proc. 80: 1340-1346 [Abstract]  
• Sierles, F. S., Brodkey, A. C., Cleary, L. M., McCurdy, F. A., Mintz, M., Frank, J., Lynn, D. J., Chao, J., Morgenstern, B. Z., Shore, W., Woodard, J. L. (2005). Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey. JAMA 294: 1034-1042 [Abstract] [Full Text]  
• Weinstein, S. L. (2005). Nothing About You... Without You. JBJS 87: 1648-1652 [Full Text]  
• Chimonas, S., Rothman, D. J. (2005). New Federal Guidelines For Physician-Pharmaceutical Industry Relations: The Politics Of Policy Formation. Health Aff (Millwood) 24: 949-960 [Abstract] [Full Text]  
• Topol, E. J., Blumenthal, D. (2005). Physicians and the Investment Industry. JAMA 293: 2654-2657 [Full Text]  
• Lambert, L. A., Jenny-Avital, E. R., Blumenthal, D. (2005). Doctors and Drug Companies. NEJM 352: 733-734 [Full Text]  
• (2004). Robin Goodfellow (43-12). Rheumatology (Oxford) 43: 1598-1598 [Full Text]  
• Studdert, D. M., Mello, M. M., Brennan, T. A. (2004). Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry -- Self-Regulation in the Shadow of Federal Prosecution. NEJM 351: 1891-1900 [Full Text]